Current Studies

NEOLEV3

A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Recruitment Status: Recruiting

Brief Summary

The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open label dose-escalation, preliminary safety and efficacy study. There will be a randomized control treatment component. Infants recognized as having neonatal seizures or as being at risk of developing seizures will be recruited and started on continuous video EEG monitoring (CEEG). Eligibility will be confirmed and consent will be obtained. In the first 2 phases of the study, neurologists will identify neonates with mild-moderate seizure burden (less than 8 minutes cumulative seizure activity per hour), appropriate for study with LEV, and exclude patients with higher seizure burden where treatment with PHB is more appropriate. Phase 3 of the dose escalation will only proceed if additional efficacy of LEV has been demonstrated in phases 1 and 2. In Phase 3 we will recruit neonates with seizures of greater severity up to 30 minute seizure burden/hour. This will make the final results of study more generalizable.

If seizures are confirmed, enrolled subjects will receive 60mg/kg of LEV. Subjects whose seizures persist or recur 15 minutes after the first infusion is complete, subjects will then be randomized in the dose escalation study. Patients in the dose escalation study will be randomly assigned to receive either higher dose LEV or treatment with the control drug PHB in a 3:1 allocation ratio, stratified by site.

NCT05610085  | Full Study Description

Condition/Diseases Studied

Intervention/Treatment Groups

Phase of Study 

2b

A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). Safety continues to be evaluated, and short-term adverse events are studied. 

Eligibility

Ages Eligible for Study:  up to 1 Month   (Child)

Sexes Eligible for Study:  All

Accepts Healthy Volunteers:  No

Inclusion Criteria:

Exclusion Criteria:


Effects of Music Based Intervention (MBI) on Neurodevelopment and Pain Response in Preterm Infants

Brief Summary

Pilot prospective randomized, double blinded, controlled study to test effect of music based intervention (MBI) on pain response and neurodevelopment in preterm infants.

NCT04286269  | Full Project Description (ClinicalTrials.gov) | NIH Project Details (RePORTER)

Project Summary

In 2018, the World Health Organization reported 15 million (>1 in 10) preterm births with rising annual rates. 50% of preterm infants suffer from neurodevelopmental impairments, and all preterm infants experience high volumes of painful procedures as part of medical care. Preterm music intervention shows immediate physiologic improvements in heart rate and oxygen saturation, as well as improved physiologic responses to pain. What remains unknown is how music impacts preterm brain maturation, neurodevelopment, and pain responses in preterm infants. 

We propose a R61 project to explore biological mechanisms of music based intervention (MBI) on preterm brain maturation and neurodevelopment using electroencephalography (EEG) and event related potentials (ERPs). EEG captures electrical potential oscillations of the brain which yields valuable information about brain function. Serial EEGs can track brain maturation in preterm infants. ERPs quantify electrical brain potentials changes time-locked with a stimulus. ERPs at 1 month corrected age test recognition memory function and cognitive processing and offers another objective measure to study the early effects of the MBI’s on neurodevelopment. 

The R61 will also explore the behavioral processes underlying effects of MBI on pain using EEG and the premature infant pain profile (PIPP). In preterm infants, central EEG amplitudes change when time-locked to a painful stimulus and PIPP scores scale pain responses with painful procedures. Specific recorded lullabies with simple arpeggiated accompaniment will be played for 6 weeks in a small randomized, blinded, controlled study of 50 medically stable 30 week preterms. Exploratory R61 findings will be assessed by specific Go/NoGo milestones that provide insight into the effects of MBI on biological mechanisms underlying neurodevelopment and behavioral processes underlying pain. 

By achieving one of the Go/NoGo milestones, the proposal progresses to the R33 proof of concept pilot clinical trial with an additional 100 randomized subjects that will assess two primary outcomes measures: 

Secondary measures would explore more nuanced aspects of neurodevelopment: 

Public Health Relevance Statement

This project addresses the following public health concerns:

We will initiate a two phased pilot clinical trial (randomized, double blinded, controlled) to support mechanistic research on the effects of music based intervention on neurodevelopment and pain response in preterm infants, with the second phase, as a proof of concept clinical trial evaluating the effects of music based intervention on late neurodevelopment and the cumulative effects of music on pain response. 

The public health relevance of this study is to provide groundbreaking results on effects of music based intervention in preterm infant health to inform future strategies on music research, given that music intervention is low risk, minimally invasive with a high potential health impact.

Condition/Diseases Studied

Intervention/Treatment Groups

Music Based Intervention

Placebo/Sham Treatment

Eligibility

Ages Eligible for Study:  28-32 Weeks (Child)

Sexes Eligible for Study:  All

Accepts Healthy Volunteers:  Yes

Inclusion Criteria:

Exclusion Criteria: